Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase i clinical trial

International Journal of Pharmaceutics

Volumn 426, Issue 1-2, 2012, Pages 67-75

  Elliott, M A ^a   Ford, S J ^a   Prasad, E ^a   Dick, L J ^a   Farmer, H ^b   Hogg, P J ^c   Halbert, G W ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anti neovascular; Arsenical; Cancer; GSAO

Indexed keywords

4 [N(S GLUTATHIONYLACETYL)AMINO]PHENYLARSONOUS ACID; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ARSENIC DERIVATIVE; GLYCINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG RETENTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; FREEZE DRYING; MAXIMUM TOLERATED DOSE; PH; POTENTIOMETRIC TITRATION; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTIOXIDANTS; ARSENICALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; FREEZE DRYING; GLUTATHIONE; GLYCINE; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATION-REDUCTION; POTENTIOMETRY; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 84857782861     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.01.024     Document Type: Article

References (11)

1. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
2. P.J. Dilda, A.S. Don, K.M. Tanabe, V.J. Higgins, J.D. Allen, I.W. Dawes, and P.J. Hogg Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains J. Natl. Cancer Inst. 97 2005 1539 1547 (Pubitemid 41631954)
3. P.J. Dilda, S. Decollogne, M. Rossiter-Thornton, and P.J. Hogg Para to ortho repositioning of the arsenical moiety of the angiogenesis inhibitor 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide results in markedly increased cellular accumulation and anti-proliferative activity Cancer Res. 65 2005 11729 11734 (Pubitemid 41821734)
4. P.J. Dilda, and P.J. Hogg Arsenical based cancer drugs Cancer Treat. Rev. 33 2007 542 564
5. P.J. Dilda, E.E. Ramsay, A. Corti, A. Pompella, and P.J. Hogg Metabolism of the tumour angiogenesis inhibitor 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid J. Biol. Chem. 283 2008 35428 35434
6. A.S. Don, O. Kisker, P. Dilda, N. Donoghue, X. Zhao, S. Decollogne, B. Creighton, E. Flynn, J. Folkman, and P.J. Hogg A peptide trivalent arsenical inhibits tumour angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells Cancer Cell 3 2003 497 509 (Pubitemid 38340296)
7. N. Donoghue, T.W. Yam, X-M. Jiang, and P.J. Hogg Presence of closely spaced protein thiols on the surface of mammalian cells Protein Sci. 9 2000 2436 2445 (Pubitemid 32105726)
8. J. Feldmann, V. Lai, W-M. Cullen, W.R. Ma, M. Lu, and X.C. Le Sample preparation and storage can change arsenic speciation in human urine Clin. Chem. 45 1999 1988 1997 (Pubitemid 29522008)
9. J.A. Vilensky, and K. Redman British anti-lewisite (dimercaprol): an amazing history Ann. Emerg. Med. 41 2003 378 383 (Pubitemid 36262633)
10. J.D. Williams Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs J. Antimicrob. Chemother. 35 1995 721 737
11. J. Zhu, Z. Chen, V. Lallemand-Breitenbach, and H. de Thé How acute promyelocytic leukaemia revived arsenic Nature Rev. Canc. 2 2002 705 714